67-73-2 Usage
Description
Fluocinolone acetonide is a synthetic fluorinated corticosteroid and a synthetic glucocorticoid VEGF inhibitor, known for its anti-inflammatory properties. It is primarily used in dermatology to reduce skin inflammation and relieve itching. It also acts as an inhibitor of tumor cells and can regulate lipid metabolism by modulating gene expression. Due to its high glucocorticoid receptor affinity, it can inhibit the expression of VEGF (vascular endothelial growth factor) in the retinal pigment epithelial cell line and inhibit TNF-α angiogenesis.
Used in Dermatology:
Fluocinolone acetonide is used as an anti-inflammatory agent for the treatment of various skin conditions, including eczema, neurodermatitis, skin pruritus, contact dermatitis, psoriasis, and dermatitis. It helps reduce skin inflammation and relieve itching, providing relief to patients suffering from these conditions.
Used in Oncology:
Fluocinolone acetonide is used as a tumor cell inhibitor, potentially offering therapeutic benefits in cancer treatment. Its ability to regulate lipid metabolism and modulate gene expression may contribute to its anti-tumor effects.
Used in Ophthalmology:
Fluocinolone acetonide is used to inhibit the expression of VEGF in the retinal pigment epithelial cell line, making it a potential treatment option for conditions related to ocular angiogenesis, such as age-related macular degeneration or diabetic retinopathy.
Used in Anti-inflammatory Applications:
As a synthetic glucocorticoid VEGF inhibitor, fluocinolone acetonide is used for its anti-inflammatory properties, which can be beneficial in managing inflammation in various medical conditions.
Corticosteroid drug
Fluocinolone acetonide is a kind of topical corticosteroids of the most significant effect and the least side effect in current china, and can cause the contraction of dermal capillary, inhibit cell proliferation or regeneration of connective tissue; it can also stabilize the intracellular lysosomal membrane and prevent the release of histamine from the intracellular lysosomal enzyme and the further tissue damage. The anti-inflammatory effects of Fluocinolone is 100 times as great s that of hydrocortisone. It has significant efficacy even at the lowest concentration (0.025%) with rapid onset rate and can significantly reduce or cure the symptoms in a few days with a relative excellent itching relief effect.
Fluocinolone acetonide is mainly used for the treatment of skin diseases to which glucocorticoid is effective such as contact dermatitis, atopic dermatitis, seborrheic dermatitis, neurodermatitis, dermatitis, eczema (especially infant eczema), pruritus disease, psoriasis, discoid lupus erythematosus, lichen planus, otitis externa and so on. Its combination with neomycin and other antibiotics can be used for the treatment of suppurative skin disease. Apply 0.025-0.05% ointment, lotion for scrubbing the affected area with 2-3 times per day. You can gently knead and make it be incorporated into the skin.
Physical and Chemical Properties
It appears as white or white-like crystalline powder and is odorless and tasteless. [α] D20+80-+88° (dioxane). It is soluble in acetone, slightly soluble in ethanol, dioxane but insoluble in water and petroleum ether. It is obtained through the sulfonic esterfication, ring-opening reaction and further 16-steps reactions starting from the 11α-hydroxy-16α, 17α-epoxy pregnane-4-ene-3, 20-dione. It can be applied to atopic dermatitis, contact dermatitis, eczema and other skin diseases.
Fluocinolone acetonide
Fluocinolone acetonide is a synthetic, fluorine-containing potent steroid. Topical administration of it can cause dermal capillary contraction and can inhibit epidermal cell proliferation or regeneration, inhibit the newborn of the fibroblast cells inside the connective tissue and stabilize the intracellular lysosomal membrane with anti-inflammatory and anti-itching effect. After topical administration, it can be absorbed through intact skin. After its absorption, similar as the metabolism of corticosteroid after systemic administration, it is mainly metabolized in the liver and can be excreted by the kidneys. Fluocinolone acetonide is suitable for treating the skin disease to which corticosteroid is effective skin such as eczema (especially eczema), neurodermatitis, skin pruritus, contact dermatitis, psoriasis, discoid lupus erythematosus, lichen planus, otitis externa, and solar dermatitis. However, it should be note that long-term or large-scale application can cause skin atrophy, telangiectasia and the occurrence of acne-like dermatitis, perioral dermatitis, folliculitis, and increased susceptibility to infection and so on. Allergic contact dermatitis can also occur in some cases.
This information is edited by Xiongfeng Dai from lookchem.
Originator
Synalar,Syntex,US,1961
Indications
Fluocinolone acetonide (Derma-Smoothe/FS, Flurosyn, Capex, Synalar) is a synthetic
fluorinated corticosteroid.
Manufacturing Process
A mixture of 1.2 grams of 6α-fluoro-16α-hydroxy-hydrocortisone, 4 cc of
acetic anhydride and 8 cc of pyridine was heated at 60°C for 2 hours and then
kept at room temperature for 2 hours. Ice and water were added and the
solid was collected, washed with water, dried and recrystallized from
methylene chloride-methanol, thus giving 1.05 grams of the 16,21-diacetate
of 6α-fluoro-16α-hydroxy-hydrocortisone (solvated) of MP 182° to 187°C;concentration of the mother liquors afforded an additional 130 mg of the same
compound, MP 184° to 187°C. By recrystallization from the same solvents
there was obtained the compound with a lower constant melting point of 175°
to 177°C.2.94 grams of the 16,21-diacetate of 6α-fluoro-16α-hydroxy-hydrocortisone
was mixed with 60 cc of dimethylformamide, 3.6 cc of pyridine and 2.4 cc of
methane-sulfonyl chloride was heated on the steam bath for 2 hours. The
diacetate of 6α-fluoro-16α-hydroxy-hydrocortisone had been prepared as set
forth above, and further dried by azeotropic distillation with benzene; the
dimethylformamide had been previously distilled. After the 2 hours on the
steam bath the mixture was cooled and poured into saturated aqueous
sodium bicarbonate solution; the product was extracted with methylene
chloride, the extract was washed with water, dried over anhydrous sodium
sulfate and the solvent was evaporated.The residue was chromatographed on 90 grams of silica gel eluting the
product with methylene chloride-acetone (9:1) and then recrystallizing from
methylene chloride-methanol. There was thus obtained 1.6 grams of the
16,21-diacetate of 6α-fluoro-δ4,9(11)-pregnadiene-16α,-17α,21-triol-3,20-dione
with MP 110° to 114°C; the analytical sample melted at 115° to 117°C,
[α]D+23.5° (chloroform), λ max. 234 to 236 nm, log ε 4.18.A mixture of 1.38 grams of the above compound and 15 cc of dioxane was
treated with 1.9 cc of a 0.5 N aqueous solution of perchloric acid and 600 mg
of N-bromoacetamide, adding the latter in the dark, in three portions, in the
course of half an hour and under continuous stirring, It was then stirred for a
further 1% hours in the dark, then the excess of reagent was decomposed by
the addition of aqueous sodium bisulfite solution and ice water was added; the
product was extracted with methylene chloride, washed with water, dried over
anhydrous sodium sulfate and the solvent was evaporated under reduced
pressure, thus giving a yellow oil consisting of the 16,21-diacetate of 6α-
fluoro-9α-bromo-16α-hydroxy-hydrocortisone which was used for the next
step without further purification.The above crude bromohydrin was mixed with 2.5 grams of potassium acetate
and 60 cc of acetone and refluxed for 6 hours, at the end of which the
acetone was distilled, water was added to the residue and the product was
extracted with methylene chloride. The extract was washed with water, dried
over anhydrous sodium sulfate and the solvent was evaporated.
Recrystallization of the residue from methanol furnished 800 mg of the 16,21-
diacetate of 6α-fluoro-9β,11β-oxido-δ4-pregnene-16α,17α,21-triol-3,20-dione
with MP 120° to 124°C; by chromatography of the mother liquors on silica gel
there was obtained 180 milligrams more of the same compound with MP 117°
to 119°C. The analytical sample was obtained by recrystallization from
methanol; it showed MP 125° to 127°C.To a solution of 1.6 grams of anhydrous hydrogen fluoride in 2.85 grams of
tetrahydrofurane and 10 cc of methylene chloride cooled to -60°C was added
a solution of 650 mg of the 16,21-diacetate of 6α-fluoro-9β,11β-oxido-δ4-
pregnene-16α,17α,21-triol-3,20-dione in 20 cc of methylene chloride and the
mixture was kept at -10°C for 72 hours. It was then poured into saturated
aqueous sodium bicarbonate solution and the organic layer was separated,
washed with water, dried over anhydrous sodium sulfate and evaporated. The residue was reacetylated by heating with 3 cc of acetic anhydride and 6 cc of
pyridine for 1 hour on the steam bath. The reagents were evaporated under
reduced pressure and the residue was chromatographed on 30 grams of silica
gel. Upon elution with methylene chloride-acetone (9:1) and recrystallization
of the residue from methylene chloride-methanol there was obtained 290 mg
of the 16,21-diacetate of 6α,9α-difluoro-16α-hydroxy-hydrocortisone which
melted with loss of solvent at 140° to 150°C. Recrystallization from acetonehexane
afforded the analytical sample which was dried at 130°C; it then
showed a MP of 182° to 185°C.
Check Digit Verification of cas no
The CAS Registry Mumber 67-73-2 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 7 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 67-73:
(4*6)+(3*7)+(2*7)+(1*3)=62
62 % 10 = 2
So 67-73-2 is a valid CAS Registry Number.
InChI:InChI=1/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13?,14?,16-,17-,19+,21-,22-,23-,24+/m0/s1
67-73-2Relevant articles and documents
Method for preparing high-purity fluocinolone acetonide
-
Paragraph 0016-0027, (2020/02/18)
The invention belongs to the technical field of preparation of steroid hormones and particularly relates to a method for preparing high-purity fluocinolone acetonide. The method comprises the steps ofmixing fluocinolone acetonide with a mixed solution, and carrying out a hydrolysis reaction, thereby obtaining the high-purity fluocinolone acetonide, wherein the mixed solution is a mixed solution of sulfite and a strong base. According to the method, an ester group of 21-position is hydrolyzed by employing a system of the strong base and the sulfite, by adding the sulfite, the reaction can be carried out at the temperature of 0 DEG C to 30 DEG C, and loci of the reaction are subjected to in-situ protection, so that the problem of deterioration of the product during hydrolysis can be excellently avoided, the product can fully meet the requirements of EP9.0 through only simple refining, the purity of the obtained product is remarkably higher than that in the prior art, and the purity andyield of a crude product are greatly improved.
NOVEL PROCESS FOR PREPARATION OF CORTICOSTEROIDS
-
, (2018/03/25)
The present invention discloses a process for the preparation of pregnadiene derivatives having formula I, their stereoisomer and intermediate thereof. Formula I wherein each substituent is independently, R1 and R2 is hydrogen or C1 –C8straight, branched alkyl chain, saturated or unsaturated cycloalkyl; R3 is hydrogen or wherein R5 represents C1-C8 straight, branched alkyl chain or cycloalkyl; R4 is hydrogen or halogen; R6 is hydrogen or halogen;
Preparation method of high-purity fluocinolone acetonide
-
Paragraph 0085; 0090; 0095; 0100; 0105; 0110; 0115; 0120, (2018/07/30)
The invention provides a preparation method of high-purity fluocinolone acetonide. The preparation method comprises the following steps: (1) performing hydrolysis reaction on 11 beta-hydroxyl-16 alpha,17-[(1-methyl ethylidene)-bis (oxygen)]-21-(acetoxy)-6 alpha,9-difluorobenzene-1,4-diene-3,20-diketone; (2) refining a 11 beta-hydroxyl-16 alpha,17-[(1-methyl ethylidene)-bis (oxygen)]-6 alpha,9-difluorobenzene-1,4-diene-3,20-diketone crude product to obtain a 11 beta-hydroxyl-16 alpha,17-[(1-methyl ethylidene)-bis (oxygen)]-6 alpha,9-difluorobenzene-1,4-diene-3,20-diketone I crystal; (3) refining the 11 beta-hydroxyl-16 alpha,17-[(1-methyl ethylidene)-bis (oxygen)]-6 alpha,9-difluorobenzene-1,4-diene-3,20-diketone I crystal to obtain a fluocinolone acetonide finished product.